Does Short-term Vitamin C Reduce Cardiovascular Risk In Type 2 Diabetes?
Notes for this study:
||Only available in figure 4
|Number of Subjects
In a randomized, controlled, crossover trial where the participants weren't blinded to the treatment they were on but the technicians and investigators were, 8 participants with well-controlled type 2 diabetes received either no supplementation, 250 mg/day, 500 mg/day, or 1000 mg/day of vitamin C for 14 day periods prior to testing. All participants received 14 days of each intervention. On the day of testing, participants ate a small breakfast with their assigned vitamin C dose and were injected with insulin until they were euglycemic. Later, they ate a high-calorie lunch and underwent blood tests for the following 5 hours. The primary outcome was surrogate markers of atherosclerotic risk, the secondary outcome was vitamin C status, and the tertiary outcomes were postprandial blood glucose and insulin.
There were no statistically significant differences between any of the groups for total cholesterol, HDL cholesterol, non-HDL cholesterol, LDL, triglycerides, oxidized LDL, glucose, insulin, adiponectin, hs-CRP, free fatty acids, IL-6, or PAI-1. The only statistically significant change in an outcome was a large and mostly comparable increase in vitamin C levels for each vitamin C dose compared with the control.